Emergent BioSolutions Inc. announced it has entered into a six-year agreement to obtain exclusive commercial rights in the U.S. and Canada for Hikma Pharmaceuticals’ KLOXXADO (naloxone HCl) Nasal Spray. KLOXXADO is an 8 mg naloxone agent approved for the emergency treatment of known or suspected opioid overdose.
This agreement strengthens Emergent’s mission to reduce opioid overdose deaths by providing a higher-dose prescription option to complement its existing NARCAN Nasal Spray 4 mg, which is available over-the-counter. The expanded portfolio allows for tailored approaches to opioid overdose reversal.
Hikma will continue to manufacture KLOXXADO Nasal Spray 8 mg, ensuring continued distribution and availability. KLOXXADO will soon be integrated into Emergent’s proprietary NARCANDirect online distribution network, serving qualified direct purchasers such as emergency medical services and government agencies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.